血清载脂蛋白A与弥漫大B细胞淋巴瘤患者疗效的相关性研究

The Study on the Correlation between Serum Apolipoprotein A and the Clinical Efficacy of Patients with Diffuse Large B-Cell Lymphoma

摘要: 目的：探讨弥漫大B细胞淋巴瘤(DLBCL)患者中载脂蛋白A (ApoA)水平的变化及其临床意义。方法：收集67例DLBCL患者的初诊时临床资料，以60例健康体检者为对照，使用R语言进行数据分析。分析数据采用t检验、Mann-Whitney U检验；相关分析采用Spearman相关性分析；采用单因素Cox回归分析和单因素Logistic回归分析ApoA水平与DLBCLH患者治疗效果的相关性。结果：DLBCL患者的ApoA水平(0.95 ± 0.25 g/L)低于正常对照组(1.29 ± 0.18 g/L)，差异具有统计学意义(P < 0.05)。不同治疗效果的DLBCL患者的ApoA水平差异具有统计学意义(P < 0.05)，两者之间成正相关(R = 0.61, P < 0.05)；单因素Cox回归分析与单因素Logistic回归分析显示ApoA可以用于初步评价DLBCL患者的治疗效果。结论：ApoA是评价DLBCL疗效的辅助指标之一。

Abstract: Objective: To investigate the changes and clinical significance of apolipoprotein A (ApoA) level in diffuse large B-cell lymphoma (DLBCL). Methods: 67 patients with DLBCL and 60 healthy normal subjects were collected. The clinical data were analyzed by R programming, measurement data were analyzed with the t-test, Mann-Whitney U test, correction analysis was used by Spearman rank correlation coefficients and regression analysis was through univariate Cox hazard analysis and univariate logistic regression. Results: The level of ApoA in patient with DLBCL (0.95 ± 0.25 g/L) was lower than normal control group (1.29 ± 0.18 g/L), and difference was statistically significant (P < 0.05). The differences between the clinical efficacy of DLBCL patients and the level of ApoA were statistically significant (P < 0.05), and there was a positive correlation between them (R = 0.61, P < 0.05); the resultes of univariate Cox regression analysis and univariate Logistic regression analysis showed that the level of ApoA can be used to evaluate the clinical efficacy of DLBCL patients. Conclusion: The level of ApoA is one of the auxiliary indicators to evaluate the clinical efficacy of DLBCL.